Search results
Fulcrum Therapeutics (NASDAQ:FULC) Raised to Buy at The Goldman Sachs Group
ETF DAILY NEWS· 11 hours agoThe Goldman Sachs Group upgraded shares of Fulcrum Therapeutics (NASDAQ:FULC – Free Report) from a neutral rating to a buy rating in a report issued on Monday, Benzinga reports ...
Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Reaffirmed by HC Wainwright
ETF DAILY NEWS· 11 hours agoFulcrum Therapeutics (NASDAQ:FULC – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Tuesday, Benzinga reports. The Goldman ...
Earnings call: Fulcrum Therapeutics partners with Sanofi on FSHD drug By Investing.com
Investing.com· 3 days agoFulcrum Therapeutics (ticker: NASDAQ:FULC) has entered into a significant collaboration with Sanofi...
Fulcrum Therapeutics stock target lifted, maintains buy on Sanofi deal By Investing.com
Investing.com· 3 days agoOn Monday, Stifel, a financial services firm, raised its price target on shares of Fulcrum...
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Simply Wall St. via Yahoo Finance· 2 days agoNonetheless, only a fool would ignore the risk that a loss making company burns through its cash too...
Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
GuruFocus.com via Yahoo Finance· 3 days agoCash Runway Guidance: Updated guidance suggests sufficient funds to cover operating requirements...
Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move...
Zacks via Yahoo Finance· 1 day agoThe consensus price target hints at a 69.2% upside potential forFulcrum Therapeutics (FULC). While...
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the...
Morningstar· 3 days agoFulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives ...
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
BioPharma Dive via Yahoo Finance· 3 days agoThe deal gives the pharma partial rights to a medicine GSK once developed for heart disease but...
Fulcrum Therapeutics Stock Climbs In Pre-market On License Deal With Sanofi For Losmapimod
RTT News· 3 days agoShares of Fulcrum Therapeutics, Inc. (FULC) were gaining more than 16 percent in the pre-market activity on the Nasdaq after the company announced a collaboration and license ...